NGM Biopharmaceuticals logo
NGM Biopharmaceuticals NGM
$ 1.54 0.0%

Annual report 2023
added 03-11-2024

report update icon

NGM Biopharmaceuticals Financial Statements 2011-2024 | NGM

Annual Financial Statements NGM Biopharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

127 M 375 M 1.37 B 2.07 B 831 M - - - - - - - -

Shares

82.5 M 80 M 77.1 M 68.5 M 50.3 M - - - - - - - -

Historical Prices

1.54 4.69 17.7 30.3 18.5 - - - - - - - -

Net Income

-142 M -163 M -120 M -102 M -42.8 M -493 K -14.2 M -6.92 M - - - - -

Revenue

4.42 M 55.3 M 77.9 M 87.4 M 104 M 109 M 77.1 M 85.6 M - - - - -

Cost of Revenue

- - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - -

Operating Income

-151 M -166 M -121 M -104 M -49.3 M -4.31 M -17.4 M - - - - - -

Interest Expense

-234 K -132 K -60 K -593 K -147 K 199 K -152 K - - - - - -

EBITDA

-149 M -162 M -115 M -97.3 M -41.7 M 2.91 M -11 M -4.83 M - - - - -

Operating Expenses

156 M 222 M 199 M 191 M 153 M - - - - - - - -

General and Administrative Expenses

37.8 M 40.5 M 36.9 M 27.2 M 23.6 M 17.3 M 14.8 M 11.8 M - - - - -

All numbers in USD currency

Quarterly Income Statement NGM Biopharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

82.7 M 82.5 M 82 M 81.9 M 80.6 M 79.3 M 78 M 78 M 77.4 M 77.1 M 76 M 70.6 M 68.8 M 68.3 M 67.4 M 67 M 65.9 M 61 M 6.81 M 6.94 M 6.53 M 6.2 M 6.13 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-28.8 M -38.3 M -47.6 M - -47.3 M -46.5 M -32.4 M - -28.9 M -36.7 M -27.5 M - -29.8 M -25.6 M -19.1 M -15.9 M -10.9 M -7.67 M -8.27 M 14.2 M -7.52 M -3.2 M -3.94 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

582 K 1.42 M 2.25 M - 7.91 M 8.29 M 20.9 M - 18.6 M 16.8 M 21.6 M - 23.5 M 19.8 M 24.4 M 31.1 M 21.6 M 25.3 M 25.6 M 47.1 M 20.8 M 22.1 M 18.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-31 M -40.6 M -50.2 M - -48.3 M -47.1 M -32.6 M - -29 M -36.6 M -27.8 M - -30 M -25.5 M -20.7 M -17.3 M -13 M -9.71 M -9.34 M 13.1 M -8.47 M -4.19 M -4.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-15 K -134 K -37 K - 78 K 5 K -45 K - 35 K -187 K 187 K - -68 K -471 K 380 K - 96 K -6 K -36 K - -14 K 95 K 22 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-30.5 M -40 M -49.6 M - -47.7 M -45.7 M -31.2 M - -27.5 M -35 M -26.3 M - -28.4 M -23.8 M -18.9 M -17.3 M -11.1 M -7.81 M -7.38 M 13.1 M -6.57 M -2.49 M -2.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

31.6 M 42 M 52.4 M - 56.2 M 55.4 M 53.5 M - 47.6 M 53.4 M 49.4 M - 53.4 M 45.3 M 45 M - 34.6 M 35 M 34.9 M - 29.3 M 26.3 M 23.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

8.67 M 9.65 M 11.6 M - 10.1 M 9.93 M 10.7 M - 8.87 M 9.82 M 8.72 M - 6.46 M 6.79 M 6.6 M - 5.61 M 6.23 M 5.37 M - 4.81 M 3.46 M 3.87 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency